AMRX
Amneal Pharma A
–
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.15B; Volume: 131.58K; AvgVol 3m: 1.10M; Beta: 1.33;
Cost estimate:
P/E: –; EPS: -1.56; EPS growth quarter/prev quarter: 38.40%;
EPS growth this year: 68.60%; EPS growth past 5 years: -40.00%;
EPS ttm: -1.56;
P/S: 0.70; P/B: 1.99; P/Cashflow: 4.60; P/FCF: 4.32;
Sales: 1.74B; Sales growth quarter/prev quarter: 14.90%; Sales growth past 5 years: 22.20%;
Profitability:
Gross Margin: 32.50%; Profit Margin: -11.20%; Operating Margin: 7.30%;
ROA – return on assets: -4.90%; ROE – return on equity: -72.30%; LT Debt/Equity: 9.36; Total Debt/Equity: 9.46;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.10%; Insider Transactions:1.05%;
Institutional Ownership: 69.90%; Institutional Transactions: 1.75%;
Data update: 07/10/2020.